Therapeutic failures of antibiotics used to treat macrolide-susceptible Streptococcus pyogenes infections may be due to biofilm formation. - Wikidata - wikimedia - TriplyDB

Therapeutic failures of antibiotics used to treat macrolide-susceptible Streptococcus pyogenes infections may be due to biofilm formation.

Therapeutic failures of antibiotics used to treat macrolide-susceptible Streptococcus pyogenes infections may be due to biofilm formation.

http://www.wikidata.org/entity/Q35073081

about

The Group A Streptococcal Carrier State Reviewed: Still an Enigma Streptococcus pyogenes biofilms-formation, biology, and clinical relevance In vivo expression of Streptococcus pyogenes immunogenic proteins during tibial foreign body infection Dispersal of Group A streptococcal biofilms by the cysteine protease SpeB leads to increased disease severity in a murine model covR Mediated Antibiofilm Activity of 3-Furancarboxaldehyde Increases the Virulence of Group A Streptococcus Environmental acidification drives S. pyogenes pilus expression and microcolony formation on epithelial cells in a FCT-dependent manner YvqE and CovRS of Group A Streptococcus Play a Pivotal Role in Viability and Phenotypic Adaptations to Multiple Environmental Stresses Relationship between expression of the family of M proteins and lipoteichoic acid to hydrophobicity and biofilm formation in Streptococcus pyogenes In vitro and in vivo antibiofilm activity of a coral associated actinomycete against drug resistant Staphylococcus aureus biofilms.Genotypic and phenotypic diversity of Lactobacillus rhamnosus clinical isolates, their comparison with strain GG and their recognition by complement system.Allelic replacement of the streptococcal cysteine protease SpeB in a Δsrv mutant background restores biofilm formation.Characterization of biofilms in different clinical M serotypes of Streptococcus pyogenes.Loss of the group A Streptococcus regulator Srv decreases biofilm formation in vivo in an otitis media model of infection.Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Rapid degradation of Streptococcus pyogenes biofilms by PlyC, a bacteriophage-encoded endolysin.Antimicrobial activities of Eugenia caryophyllata extract and its major chemical constituent eugenol against Streptococcus pneumoniae.Hyaluronic acid derived from other streptococci supports Streptococcus pneumoniae in vitro biofilm formation.One pot synthesis and anti-biofilm potential of copper nanoparticles (CuNPs) against clinical strains of Pseudomonas aeruginosa.The Small Molecule DAM Inhibitor, Pyrimidinedione, Disrupts Streptococcus pneumoniae Biofilm Growth In Vitro.emm Types, virulence factors, and antibiotic resistance of invasive Streptococcus pyogenes isolates from Italy: What has changed in 11 years?Throat culture positivity rate and antibiotic susceptibility pattern of beta-hemolytic streptococci in children on secondary prophylaxis for rheumatic heart disease In VitroStreptococcus pneumoniae Biofilm Formation and In Vivo Middle Ear Mucosal Biofilm in a Rat Model of Acute Otitis Induced by S. pneumoniae.Response of Different Antibiotic Resistant Group of Streptococcus pyogenes to Environmental Stresses.Inhibition of Quorum Sensing-Controlled Virulence Factors and Biofilm Formation in Pseudomonas aeruginosa by Culture Extract from Novel Bacterial Species of Paenibacillus Using a Rat Model of Chronic Lung Infection.Protective mechanisms of respiratory tract Streptococci against Streptococcus pyogenes biofilm formation and epithelial cell infection.Efficient Eradication of Mature Pseudomonas aeruginosa Biofilm via Controlled Delivery of Nitric Oxide Combined with Antimicrobial Peptide and Antibiotics.Biofilm formation by group A Streptococcus: a role for the streptococcal regulator of virulence (Srv) and streptococcal cysteine protease (SpeB).Antibiofilm activity, compound characterization, and acute toxicity of extract from a novel bacterial species of paenibacillus.Antimicrobial and Anti-Virulence Activity of Capsaicin Against Erythromycin-Resistant, Cell-Invasive Group A Streptococci.Betulin inhibits virulence and biofilm of Streptococcus pyogenes by suppressing ropB core regulon, sagA and dltA.Involvement of T6 pili in biofilm formation by serotype M6 Streptococcus pyogenes.Usnic acid, a lichen secondary metabolite inhibits Group A Streptococcus biofilms.Inhibition of Growth and Gene Expression by PNA-peptide Conjugates in Streptococcus pyogenes.Examine the characterization of biofilm formation and inhibition by targeting SrtA mechanism in Bacillus subtilis: a combined experimental and theoretical study.Gene expression profile of early in vitro biofilms of Streptococcus pneumoniae.Damage to ciliated epithelium in chronic rhinosinusitis: what is the role of bacterial biofilms?Phenotypic and genotypic features of first biofilm forming nasopharyngeal colonized Streptococcus pneumoniae isolates.Biofilm formation of beta-hemolytic group G Streptococcus dysgalactiae subspecies equisimilis isolates and its association with emm polymorphism.Antibiofilm activity of α-amylase from Bacillus subtilis S8-18 against biofilm forming human bacterial pathogens.Phenol, 2,4-bis(1,1-dimethylethyl) of marine bacterial origin inhibits quorum sensing mediated biofilm formation in the uropathogen Serratia marcescens.

P2860

Q26775604-58DD8EEE-0E19-4FE8-9147-81A2FA269689 Q28387682-F134487D-A2AC-4C6A-AD1E-A84640BAF8E5 Q28395445-EBD20145-BB62-472D-9290-A812B61F27AF Q28477890-F0D07F52-16CB-4186-8412-2F21EDB4590F Q28547259-2B641AD0-DD8A-4CBA-B987-24E227316B50 Q28748545-FFECD62D-667A-42F1-8BD3-DBFC3BCDA548 Q29248567-59E50174-92BA-4449-BD12-E9CE9FA8A19A Q33398535-AA2F7F73-933B-4829-A85F-6CE04B469357 Q33656766-B61E4FF6-4AC9-423E-B3FD-70E09BD30271 Q33663517-5CDEC012-0D7D-4A4A-A6BA-CFF555523598 Q33738262-ABC27D39-6653-4834-8CF0-2DDDA3150045 Q33813799-DB3C5077-BB66-4D9D-8B86-6EE123560BD6 Q34290864-87F61D95-370E-4987-A270-2A251C9CC98E Q34413457-9EE052C0-8FEF-4213-9768-0BA7F1F4DB5D Q34655703-CBA34B04-9B19-4CBE-8291-87D452603F37 Q34675266-E58E1560-F4C6-46A2-B4F5-4C8667F9B55D Q35028623-74E8E33E-DD4A-4C20-8AD4-5C58E78C112D Q35658110-26AFC4DB-1AA1-4B66-93CF-3ED88B80082A Q35797408-8583BB7F-3537-4B77-8F93-8746C351219F Q35913752-B716EC3E-9EED-46A7-911D-2383B3E7D6A7 Q36143527-C37B6D2A-C84A-4530-9C83-E2DC3570B663 Q36220069-F67D9F6C-80C6-4389-B3A9-CF1820BA0413 Q36285154-BB742733-DB6B-4454-95E7-647F5FC4970E Q36556657-0AD5E305-981E-451D-B10B-B72EFB649425 Q36599153-E774E6E7-639B-4082-96FB-48B1D06350B7 Q37182594-8124569A-2241-4FD3-9D6B-195C5FC71F0B Q37245274-8381A24D-41F2-49E8-A49D-D98DF1D1FA8D Q37695900-C6B8521F-609D-41D1-ACED-1BFDB6C6A50B Q39180086-753C983E-13DC-4FA3-97BD-BDF139534756 Q40551293-DE5D252F-32D4-4BDB-9DEE-FAE8ED84C09D Q40870774-C4088DD8-8B72-42D3-AB3B-1D172478109C Q41678717-2BACF0FC-0B8F-44B3-8C74-C1DEC13FECB6 Q41866988-6A59DBFB-28D8-4546-AD3F-F5234E273A86 Q45755787-FD2BC17F-B9C8-4D2B-ACDE-6FBD32B520DE Q45924918-1ACB55CA-D1BA-4181-AAC4-29008CC64817 Q45977754-57D822D2-1EA5-473F-9376-F397386AA789 Q47104673-C77F9517-FFBC-4C1C-9C16-17C2C313418C Q47699093-ED2CC47F-45C6-418D-8951-3345B7CBD0E1 Q52621897-BE01425B-672F-4AA6-A780-48595FB5A173 Q52654845-CBD7A875-7B63-4FA2-94BF-D8A7A9382B6E

P2860

Therapeutic failures of antibiotics used to treat macrolide-susceptible Streptococcus pyogenes infections may be due to biofilm formation.

http://www.wikidata.org/entity/Q35073081

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Therapeutic failures of antibi ...... y be due to biofilm formation.

@ast

Therapeutic failures of antibi ...... y be due to biofilm formation.

@en

type

label

Therapeutic failures of antibi ...... y be due to biofilm formation.

@ast

Therapeutic failures of antibi ...... y be due to biofilm formation.

@en

prefLabel

Therapeutic failures of antibi ...... y be due to biofilm formation.

@ast

Therapeutic failures of antibi ...... y be due to biofilm formation.

@en

P1433

Q35073081-F438A1EA-56FA-41A4-B9B6-C8AE20BDE526

P1476

Q35073081-4E204141-8BF5-434F-90F4-1C3517534F00

P2093

Q35073081-2BDF038A-B770-4AF2-B36C-AE8CAC19414A

Q35073081-7485DDC5-F22D-4204-91FA-9C25099A3A94

Q35073081-77E1428B-2311-45F4-B667-83203CBD1209

Q35073081-7CD24423-D58F-46F8-8471-5E441DD74022

Q35073081-892BA1B6-1059-4EF6-8809-C6E59435454A

Q35073081-8D764B8C-F652-49AE-A036-EF0CA60134EA

Q35073081-D0C08EE0-DC07-4FB6-9E4E-A13B19F0AB5E

Q35073081-D8141833-01FA-4797-B6A1-AB58CE6A9756

Q35073081-F3926289-AD0E-47C8-BF74-EB2B20519D7A

P2860

Q35073081-0B4B00FB-901C-4B98-8442-171D377EC3B8

Q35073081-0F0EB623-5629-4FD7-81FC-9B84FEBABC60

Q35073081-1F75AF95-98C3-4291-9FAB-A89EA7032A42

Q35073081-26BEBF00-CB44-44A0-9054-2BEFF873A287

Q35073081-271A50AC-2A97-41A0-9A68-99B21DE3E6D3

Q35073081-29A3E0AC-1CB6-47AF-8D19-10595F1E1149

Q35073081-363D929A-7E4B-4E7E-BCD2-ECC968B6102B

Q35073081-476AE9BF-957A-4591-AF53-C3A730A94FFB

Q35073081-52DD9F51-BE27-4E04-8786-32DA370E66D3

Q35073081-52F30176-0CA5-4A66-AB03-B47410FC5319

P304

Q35073081-EBCE2340-BAAF-4216-A019-58FD2E69B2A3

P31

Q35073081-7E8B72DE-C19E-44AA-B868-E9DBCB819E61

P356

Q35073081-6A51ABEF-9509-4EBC-BAEF-0852BC43DE21

P407

Q35073081-A12FAF51-B3C0-4F1A-B8DD-E1DEBB3FDA3B

P433

Q35073081-F17FDB30-0E8C-4A33-8C1C-F4EF90D0E257

P478

Q35073081-01A874C0-18DF-43FE-820D-17C0793DC9BA

P577

Q35073081-042B371F-5809-4A0C-9AC7-BE25012A651F

P698

Q35073081-766D9D38-8EDD-4CCE-BDBB-6A50DFC35590

P921

Q35073081-1DBD4B81-6329-4E5E-AF87-A25536DE307A

Q35073081-2BC0A649-E649-4B3E-BFAF-8D0E67D6B93D

P932

Q35073081-06F239A0-2B58-47EA-B40D-E7A29B3A2ACC

P356

P1433

Journal of Clinical Microbiology

P1476

Therapeutic failures of antibi ...... y be due to biofilm formation.

@en

P2093

Bruna Facinelli

http://www.w3.org/2001/XMLSchema#string

Eleonora Giovanetti

http://www.w3.org/2001/XMLSchema#string

Giovanna Alfarone

http://www.w3.org/2001/XMLSchema#string

Graziella Orefici

http://www.w3.org/2001/XMLSchema#string

Lucilla Baldassarri

http://www.w3.org/2001/XMLSchema#string

Marco Pataracchia

http://www.w3.org/2001/XMLSchema#string

Monica Imperi

http://www.w3.org/2001/XMLSchema#string

Roberta Creti

http://www.w3.org/2001/XMLSchema#string

Simona Recchia

http://www.w3.org/2001/XMLSchema#string

P2860

Biofilms: survival mechanisms of clinically relevant microorganisms.

Pathogenesis of group A streptococcal infections

Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis

Characterization of biofilm formation by clinically relevant serotypes of group A streptococci.

Variations in emm type among group A streptococcal isolates causing invasive or noninvasive infections in a nationwide study

Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America.

Molecular basis of group A streptococcal virulence.

Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotising soft-tissue infections.

Constitutive expression of fibronectin binding in Streptococcus pyogenes as a result of anaerobic activation of rofA.

Presence of the tet(O) gene in erythromycin- and tetracycline-resistant strains of Streptococcus pyogenes and linkage with either the mef(A) or the erm(A) gene.

P304

2721-2727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JCM.00512-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16891483

http://www.w3.org/2001/XMLSchema#string

P921

P932

1594624

http://www.w3.org/2001/XMLSchema#string